Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 14/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10206026 | 1.00 | SMYD3 (0.62) | SMYD3KMT2AFASN | |
| SCHEMBL572810 | 1.00 | SMYD3 (0.62) | SMYD3KMT2AFASN | |
| Hydrochloric Acid SCHEMBL572762 | 0.98 | SMYD3 (0.60) | SMYD3KMT2AFASN | |
| Hydrochloric Acid SCHEMBL572763 | 0.98 | SMYD3 (0.60) | SMYD3KMT2AFASN | |
| SCHEMBL103477 | 0.89 | — | — | |
| SCHEMBL18880078 | 0.89 | SMYD3 (0.47) | SMYD3KMT2AFASN | |
| SCHEMBL13625350 | 0.86 | SMYD3 (0.60) | SMYD3KMT2A | |
| SCHEMBL3401705 | 0.86 | SMYD3 (0.60) | SMYD3KMT2A | |
| SCHEMBL15480842 | 0.83 | SMYD3 (0.43) | SMYD3KMT2AFASN | |
| SCHEMBL24996526 | 0.81 | SMYD3 (0.64) | SMYD3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-02-09 | — | — | US | disclosed |
| CN-105593224-A | Novel quinazolinones as bromodomain inhibitors | ZENITH EPIGENETICS CORP | 2016-05-18 | — | — | CN | disclosed |
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2016-02-18 | — | — | US | disclosed |
| US-20150306086-A1 | MODULATING CERTAIN TYROSINE KINASES | TESARO, INC. | 2015-10-29 | — | — | US | disclosed |
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| CN-104202982-A | Modulating certain tyrosine kinases | TESARO INC | 2014-12-10 | — | — | CN | disclosed |
| EP-2779833-A1 | MODULATING CERTAIN TYROSINE KINASES | Tesaro Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2611784-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | Amgen, Inc (US) | 2013-07-10 | — | — | EP | disclosed |
| CN-103168032-A | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC | 2013-06-19 | — | — | CN | disclosed |
| WO-2013074518-A1 | MODULATING CERTAIN TYROSINE KINASES | TESARO, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| WO-2012018668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | SMYD3 1388/4885KMT2A 493/4885FASN 630/4885 |
| US-20150306086-A1 | MODULATING CERTAIN TYROSINE KINASES | ABL1, LCK, FLT3 | SMYD3 1704/4885KMT2A 818/4885FASN 4573/4885 |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | NLN, GLS, PRNP | SMYD3 3594/4885KMT2A 3429/4885FASN 694/4885 |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | SMYD3 1388/4885KMT2A 493/4885FASN 630/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | SMYD3 4129/4885KMT2A 3551/4885FASN 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.